Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.

Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A.

Eur Urol. 2012 Apr;61(4):834-9. doi: 10.1016/j.eururo.2011.12.011. Epub 2011 Dec 13.

PMID:
22204745
2.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.

Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.

PMID:
23608668
3.

Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).

Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M.

Eur Urol. 2012 Sep;62(3):507-14. doi: 10.1016/j.eururo.2011.12.056. Epub 2012 Jan 5.

PMID:
22236796
4.
5.

Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.

Kuo HC, Liao CH, Chung SD.

Eur Urol. 2010 Dec;58(6):919-26. doi: 10.1016/j.eururo.2010.09.007. Epub 2010 Sep 17.

PMID:
20864251
6.

Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.

Veeratterapillay R, Harding C, Teo L, Vasdev N, Abroaf A, Dorkin TJ, Pickard RS, Hasan T, Thorpe AC.

Int J Urol. 2014 Feb;21(2):175-8. doi: 10.1111/iju.12205. Epub 2013 Jul 2.

7.

Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.

Gamé X, Khan S, Panicker JN, Kalsi V, Dalton C, Elneil S, Hamid R, Dasgupta P, Fowler CJ.

BJU Int. 2011 Jun;107(11):1786-92. doi: 10.1111/j.1464-410X.2010.09791.x. Epub 2010 Oct 29.

8.

Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity.

Peyronnet B, Roumiguié M, Castel-Lacanal E, Guillotreau J, Malavaud B, Marque P, Rischmann P, Gamé X.

Neurourol Urodyn. 2016 Feb;35(2):267-70. doi: 10.1002/nau.22712. Epub 2014 Dec 18.

PMID:
25524826
9.

The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.

Chen YC, Kuo HC.

Neurourol Urodyn. 2014 Jan;33(1):129-34. doi: 10.1002/nau.22395. Epub 2013 Mar 12.

PMID:
23494629
10.

Botulinum toxin injections for adults with overactive bladder syndrome.

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. Review.

PMID:
22161392
11.

Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.

Marcelissen TA, Rahnama'i MS, Snijkers A, Schurch B, De Vries P.

World J Urol. 2017 Feb;35(2):307-311. doi: 10.1007/s00345-016-1862-y. Epub 2016 Jun 7.

PMID:
27272312
12.

Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.

Alloussi SH, Lang Ch, Eichel R, Al-Kaabneh A, Seibold J, Schwentner C, Alloussi S.

World J Urol. 2012 Jun;30(3):367-73. doi: 10.1007/s00345-011-0736-6. Epub 2011 Aug 13.

PMID:
21842216
13.

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.

Hsiao SM, Lin HH, Kuo HC.

PLoS One. 2016 Jan 29;11(1):e0147137. doi: 10.1371/journal.pone.0147137. eCollection 2016.

14.

Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.

Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, Hermieu JF, Amarenco G, Karsenty G, Saussine C, Barbot F; VESITOX study group in France.

Eur Urol. 2012 Mar;61(3):520-9. doi: 10.1016/j.eururo.2011.10.028. Epub 2011 Oct 25.

PMID:
22036776
15.

Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis.

Cui Y, Wang L, Liu L, Zeng F, Niu J, Qi L, Chen H.

Urol Int. 2013;91(4):429-38. doi: 10.1159/000351037. Epub 2013 Aug 16. Review.

PMID:
23970316
16.

Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.

Osborn DJ, Kaufman MR, Mock S, Guan MJ, Dmochowski RR, Reynolds WS.

Neurourol Urodyn. 2015 Sep;34(7):675-8. doi: 10.1002/nau.22642. Epub 2014 Jun 29.

17.

Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?

Sahai A, Sangster P, Kalsi V, Khan MS, Fowler CJ, Dasgupta P.

BJU Int. 2009 Mar;103(5):630-4. doi: 10.1111/j.1464-410X.2008.08076.x. Epub 2008 Oct 16.

18.
19.
20.

Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries.

Kuo HC, Liu SH.

Neurourol Urodyn. 2011 Nov;30(8):1541-5. doi: 10.1002/nau.21146. Epub 2011 Jun 29.

PMID:
21717505

Supplemental Content

Support Center